1991至2000年间接受原发性先天性青光眼手术患者的长期结局:单中心数据库研究
该回顾性研究纳入1991年1月至2000年12月期间因原发性先天性青光眼接受初次小梁切开-小梁切除术(未使用丝裂霉素C)的121例患者共220眼,并在2021年1月至2022年1月完成至少20年随访。Kaplan-Meier分析显示1年、10年、20年完全成功率分别为90.7%、78.9%、44.5%;视力结局良好、中等、差的比例分别为33.2%、16.4%、50.4%,近视占68.9%。结论认为小梁切开-小梁切除术是有用的手术方式,可提供良好的眼压控制和中等视力恢复,并维持20年。
要点
- 20年完全成功率为44.5%,1年和10年分别为90.7%和78.9%。
- 视力结局良好、中等、差的比例分别为33.2%、16.4%、50.4%,近视占68.9%。
- 初次小梁切开-小梁切除术后14.4%的眼需第二次手术控制眼压,6眼因疼痛性盲眼行眼球摘除。
核心结论
- 在该大型原发性先天性青光眼队列中,小梁切开-小梁切除术是有用的手术方式,可提供良好的眼压控制和中等视力恢复,并在术后20年随访中维持。
研究设计与样本
- 回顾性研究,纳入1991年1月至2000年12月期间因原发性先天性青光眼接受手术、并于2021年1月至2022年1月返回随访的121例患者共220眼。
- 所有患者接受初次小梁切开-小梁切除术(未使用丝裂霉素C)作为初始手术。
- 采用混合效应模型(最大似然估计)估计基于眼的变量并比较不同访视,Kaplan-Meier生存分析估计手术和功能成功概率,Cox比例风险回归(三明治聚类估计)评估失败和视力不良结局的危险因素。
主要发现
- Kaplan-Meier生存分析显示1年、10年和20年完全成功率分别为90.7%、78.9%和44.5%。
- 单变量分析中,接受任何额外非青光眼眼内手术的患者手术失败率更高;多变量分析中无临床参数与失败显著相关。
- 视力结局良好、中等和差的眼比例分别为33.2%、16.4%和50.4%;近视见于68.9%的眼。
- 接受初次小梁切开-小梁切除术的眼中有28眼(14.4%)需第二次手术控制眼压。
- 未发生显著术中并发症;6眼因疼痛性盲眼需行眼球摘除。
关键数值与推荐
- 完全成功定义为眼压≥6 mmHg且≤21 mmHg,不使用青光眼药物。
- 条件成功定义为需使用最多2种青光眼药物。
- 失败定义为使用超过2种青光眼药物仍眼压不受控、需第二次降眼压手术、慢性低眼压(连续2次访视眼压<6 mmHg)或任何威胁视力的并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To estimate the long-term surgical and visual outcomes in patients with primary congenital glaucoma (PCG) who completed at least 20 years of follow-up. DESIGN: Retrospective study. PARTICIPANTS: Two hundred twenty eyes of 121 patients undergoing surgery for PCG between January 1991 and December 2000 and who returned for a follow-up visit from January 2021 through January 2022. METHODS: Retrospective review of medical records of patients who underwent primary combined trabeculotomy-trabeculectomy (CTT) without mitomycin C as an initial procedure. Success was defined as complete when intraocular pressure (IOP) was ≥ 6 mmHg and ≤ 21 mmHg without glaucoma medication and as qualified when up to 2 glaucoma medications were required. Failure was defined as uncontrolled IOP with more than 2 glaucoma medications, need for a second IOP-lowering procedure, chronic hypotony (IOP < 6 mmHg on 2 consecutive visits), or any sight-threatening complication. A mixed-effects model using maximum likelihood estimation was used in estimation of eye-based variables and to make comparisons between different visits. Kaplan-Meier survival analysis was used to estimate the probabilities of surgical and functional successes. Cox proportional hazards regression using sandwich clustered estimation was used to evaluate risk factors for failure and poor visual outcome. MAIN OUTCOME MEASURES: Primary outcome measure was the proportion of patients who demonstrated complete success over the 20-year follow-up. Secondary outcome measures included rate of surgical failure and need for reoperation for glaucoma, visual acuity, refractive errors, risk factors for poor outcome, and complications. RESULTS: Kaplan-Meier survival analysis revealed 1-year, 10-year, and 20-year complete success rates of 90.7%, 78.9%, and 44.5%, respectively. In univariate analysis, surgical failure was higher among patients with any additional non-glaucoma intraocular surgery. None of the clinical parameters were associated significantly with failure in multivariable analysis. Overall, the proportion of eyes with good, fair, and poor visual outcomes was 33.2%, 16.4%, and 50.4%, respectively. Myopia was seen in 68.9% eyes. Twenty-eight eyes of those who underwent primary CTT (14.4%) required second surgery for IOP control. No significant intraoperative complications occurred. Six eyes required enucleation because of painful blind eye. CONCLUSIONS: In this large cohort of patients with PCG, CTT is a useful procedure. It provides good IOP control and moderate visual recovery that remained over a 20-year follow-up after surgery. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Mandal AK, Gothwal VK, Mohamed A, et al. Long-term Outcomes in Patients Undergoing Surgery for Primary Congenital Glaucoma between 1991 and 2000: A Single-Center Database Study. Ophthalmology. 2023. PMID: 37454696. doi:10.1016/j.ophtha.2023.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。